Latest news with #LuisaHector
Globe and Mail
2 days ago
- Business
- Globe and Mail
AstraZeneca (AZN) Receives a Buy from Berenberg Bank
In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on AstraZeneca, with a price target of £142.00. The company's shares closed yesterday at p10,340.00. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Hector is a 3-star analyst with an average return of 3.0% and a 56.25% success rate. Hector covers the Healthcare sector, focusing on stocks such as Sanofi, AstraZeneca, and Roche Holding AG. In addition to Berenberg Bank, AstraZeneca also received a Buy from UBS's Matthew Weston in a report issued on July 7. However, yesterday, Deutsche Bank reiterated a Hold rating on AstraZeneca (LSE: AZN). AZN market cap is currently £158.4B and has a P/E ratio of 25.91. Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AZN in relation to earlier this year.
Business Insider
3 days ago
- Business
- Business Insider
AstraZeneca price target raised to $97 from $93 at Berenberg
Berenberg analyst Luisa Hector raised the firm's price target on AstraZeneca (AZN) to $97 from $93 and keeps a Buy rating on the shares. The firm increased its 2030 revenue forecast by 3% to $79B, ahead of consensus, saying the company has seen 'substantial pipeline progress already this year.' AstraZeneca shares should price in a larger pipeline valuation, the analyst tells investors in a research note. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Business Insider
3 days ago
- Business
- Business Insider
AstraZeneca (AZN) Receives a Buy from Berenberg Bank
In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on AstraZeneca, with a price target of £142.00. The company's shares closed yesterday at p10,340.00. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Hector is a 3-star analyst with an average return of 3.0% and a 56.25% success rate. Hector covers the Healthcare sector, focusing on stocks such as Sanofi, AstraZeneca, and Roche Holding AG. In addition to Berenberg Bank, AstraZeneca also received a Buy from UBS's Matthew Weston in a report issued on July 7. However, yesterday, Deutsche Bank reiterated a Hold rating on AstraZeneca (LSE: AZN). AZN market cap is currently £158.4B and has a P/E ratio of 25.91. Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AZN in relation to earlier this year.
Yahoo
16-06-2025
- Business
- Yahoo
Berenberg Bank Maintains a Hold Rating on Novartis (NVS)
Novartis AG (NYSE:NVS) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. On June 12, Berenberg Bank analyst Luisa Hector maintained a Hold rating on Novartis AG (NYSE:NVS) and set a price target of CHF89.00. The same day, the company reported statistically significant improvements in the Phase IIIB APPULSE-PNH study. The study demonstrated clinically meaningful improvements in hemoglobin (Hb) levels of 2.01 g/dL on average in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who switched to Fabhalta. A doctor holding a microscope in front of a laboratory sample of healthcare products. None of the patients treated with Fabhalta required transfusions, experienced major adverse vascular events during the treatment period, or experienced breakthrough hemolysis (BTH). Novartis AG (NYSE:NVS) develops, manufactures, and markets healthcare products. The company operates through the Innovative Medicines, Sandoz, and Corporate segments. It is the tenth-best drug stock to invest in now and is headquartered in Basel, Switzerland. While we acknowledge the potential of NVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-06-2025
- Business
- Yahoo
Berenberg Bank Remains a Buy on Sanofi (SNY), Sets a €118 Price Target
Sanofi (NASDAQ:SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Berenberg Bank analyst Luisa Hector maintained a Buy rating on Sanofi (NASDAQ:SNY) on June 12, setting a price target of €118.00. The rating followed the company's presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, highlighting various growth drivers within Specialty Care that bring an optimistic light to its operations. Dozens of pharmaceutical capsules piled on top of one another to show the scale of the company's drug contributions to the industry. Brian Foard, Head of Specialty Care at Sanofi (NASDAQ:SNY), stated that the product dupilumab is expected to undergo double-digit CAGR growth between 2023 and 2030, delivering an estimated EUR 22 billion by the end of the forecast period. He said that Sanofi's (NASDAQ:SNY) recently launched assets, such as ALTUVIIIO and Qfitlia, further add to this positive outlook. This also includes SARCLISA, the first FDA-approved treatment for adults with newly diagnosed multiple myeloma, which is continuing to expand its indications from both oncology and multiple myeloma perspectives. The company thus presented a growth story at the conference, including in neurology, where it anticipates a reentry into the MS space through the upcoming launch of tolebrutinib. Sanofi (NASDAQ:SNY) ranks 11th on our list of the best drug stocks to buy according to hedge funds. It researches, produces, and distributes pharmaceutical products. The company's operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments. While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
